Patients treated with A9 biolimus eluting stent with biodegradable polymer (Nobori, Terumo) can receive only six months of dual antiplatelet therapy (DAPT) with no increase in adverse events, compared against more prolonged treatments. The net adverse clinical and cerebrovascular events that included all cause death, MI, cerebrovascular events and major bleeding was: 1.92% for<a href="https://solaci.org/en/2016/09/07/six-month-dapt-enough-for-nobori-bes/" title="Read more" >...</a>
This study, presented in Rome at the European Society of Cardiology Congress 2016 and published simultaneously online in the Journal of the American College of Cardiology (JACC), has identified a post-TAVI valve thrombosis rate of 7% using multidetector computerized tomography (CT). However, the vast majority of cases were completely asymptomatic. Previous studies had shown<a href="https://solaci.org/en/2016/09/07/a-study-on-valve-thrombosis-after-tavi/" title="Read more" >...</a>
Courtesy of Dr. Santiago F. Coroleu. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention (PCI) reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). However, the lack of information to accurately predict the occurrence of each event in out-of-hospital patients under<a href="https://solaci.org/en/2016/08/17/optimal-duration-of-dapt-how-to-predict-long-term-events/" title="Read more" >...</a>
All studies on diabetics have shown these patients have higher risk rates of thrombotic events. This study sought to determine the optimal antiaggregation therapy with ticagrelor to prevent thrombotic events in diabetic patients with prior MI. The study analyzed diabetic patient and non-diabetic patient subgroups (n=6806 and n=14355, respectively) from the PEGASUS–TIMI 54<a href="https://solaci.org/en/2016/07/29/ticagrelor-reduces-events-in-diabetics-with-prior-mi/" title="Read more" >...</a>
Original Title: Ticagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease. Reference: Marc P. Bonaca et al. J Am Coll Cardiol. 2016 Jun 14;67(23):2719-28. Peripheral artery disease is associated with high rates of ischemic and bleeding events in patients with prior myocardial infarction. This study evaluates the safety<a href="https://solaci.org/en/2016/07/08/does-ticagrelor-reduce-events-in-peripheral-artery-disease/" title="Read more" >...</a>
Original Title: Pharmacodynamic Effects of Switching from Prasugrel to Ticagrelor Results of the Prospective, Randomized SWAP-3 Study Reference: J Am Coll Cardiol Intv. 2016;() Epub ahead of print. Courtesy of Dr. Agustín Vecchia. At present, the pharmacodynamic effects of switching from prasugrel to ticagrelor in patients under dual APT remain unknown. The present prospective, randomized,<a href="https://solaci.org/en/2016/05/26/effects-of-switching-from-prasugrel-to-ticagrelor-in-patients-with-acs/" title="Read more" >...</a>
Original Title: Spontaneous MI after Non–ST-Segment Elevation Acute Coronary Syndrome Managed without Revascularization. The TRILOGY ACS Trial. Reference: Renato D. Lopes et al. J Am Coll Cardiol. 2016;67(11):1289-1297. Patients admitted with acute coronary syndromes (ACS) and especially those managed conservatively without revascularization, are at high risk of a new spontaneous infarction. However, MI risk rate<a href="https://solaci.org/en/2016/04/28/conservative-management-of-mi-risk-in-acs/" title="Read more" >...</a>
The use of morphine in patients undergoing ST elevation acute coronary syndromes is associated to higher platelet reactivity and lower thrombolysiscapacity, according to this small study. The negative effects seem to resolve 2 days after administration. This transient effect is believed to be the result of the inhibition of the normal muscular activity of the<a href="https://solaci.org/en/2016/04/08/morphine-increases-platelet-reactivity-in-infarctions/" title="Read more" >...</a>
Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Reference: Levine GN et al. Circulation. 2016 Mar 29. [Epub ahead of print]. Courtesy of Dr. Alejandro Lakowsky. The new ACC-AHAGuidelines on the optimal duration of dual antiplatelet therapy(DAPT) in patients with coronary artery disease have just been<a href="https://solaci.org/en/2016/04/01/optimal-duration-of-dual-antiplatelet-therapy-new-acc-aha-guidelines/" title="Read more" >...</a>
Original Title: Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-Year results from SORT OUT IV. Reference: Jensen LO et al. J Am Coll Cardiol. 2016;67:751-762. Reassuring long term outcomes from SORT OUT IV confirm the safety and efficacy of second generation everolimus eluting stents (EES) over first generation DES. The difference at 5-year follow up<a href="https://solaci.org/en/2016/02/17/sort-out-iv-at-5-years-second-generation-des-efficacy-confirmed/" title="Read more" >...</a>